Article July 1, 1998

Chairman's Overview/The Place of Reboxetine in Antidepressant Therapy

Stuart A. Montgomery, M.D.

J Clin Psychiatry 1998;59(suppl 14):26-29

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

A wide range of antidepressants is now availableincluding the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), reversiblemonoamine oxidase-A inhibitors (RIMAs), serotonin selectivereuptake inhibitors (SSRIs), serotonin and norepinephrinereuptake inhibitors (SNRIs), and atypical antidepressantssuch as mirtazapine and nefazodone. However,clinicians still face a number of problems when selectingthe most appropriate antidepressant for a given patient.TCAs are effective in a wide range of patients, but they dohave significant drawbacks in terms of their tolerabilityand safety in overdose, reflecting actions at sites otherthan those involved in the antidepressant effect.